本期导读： 高校群体正成为创投行业的一股新力量。 作者丨FOFWEEKLY 本期推荐阅读5分钟 近年来，高校在科技创新链条中的定位发生新变化：除了输送顶尖人才、孵化前沿技术外，越来越 多高校开始突破传统边界，积极投身于创投行业。 天津大学、复旦大学、上海交通大学、中南大学、香港科技大学、南方科技大学等诸多高校通过 "设立基金或母基金" 的方式躬身入局，逐渐形成了创投领域的新力量。 日前，又一所211高校强势入场了。 近两年，机器人、人工智能、半导体等行业热潮涌动， 创投市场掀起新一轮科技投资风暴。而在 这场科技与资本的盛宴中，手握源头技术的高校正从幕后走向台前，纷纷加入战局，成为行业发展 不可忽视的新兴力量。 高校相继入局 2025年以来，随着AI、机器人、低空经济等赛道的持续火热，行业的投资热情进一步被调动，而 各地对未来产业的布局也持续深入。 这次是武汉理工大学。 211高校闯入VC圈 VC圈高校阵容又添新军。 近日，武汉理工大学举行首届科技成果投融资峰会。会上，举行了武汉理工大学国家大学科技园优 化重塑启动仪式。发起设立武理科创基金，基金由武汉理工与长江产业投资集团联合发起设立， 首期募资规模为10亿元 ...

Core Viewpoint - The article discusses the generational conflict in parenting styles between young parents and their own parents, highlighting the challenges of balancing love and discipline in child-rearing [4][7]. Group 1: Generational Conflict - The tension arises from differing educational philosophies, with grandparents often indulging the child while parents enforce strict rules [1][2]. - The grandparents' indulgence is linked to their desire for emotional fulfillment and a sense of value after retirement, leading to a clash with the parents' focus on discipline and self-regulation [4][5]. - The lack of effective communication and mutual understanding exacerbates the situation, making it difficult to establish a cohesive educational approach [2][3]. Group 2: Solutions and Strategies - To resolve the conflict, the article suggests using "emotional connection" instead of a "right vs. wrong" approach, employing techniques like the "sandwich communication method" to facilitate discussions [5][6]. - Establishing a "family agreement" that delineates roles and responsibilities can help clarify expectations, with parents leading educational efforts while grandparents focus on daily care [6]. - Encouraging collaboration by involving grandparents in non-material aspects of child-rearing can transform conflicts into cooperative opportunities, fostering a supportive environment for the child [6][7].

Core Viewpoint - In 2024, Yiling Pharmaceutical (002603) faced competitive pressure in the pharmaceutical industry and adhered to a strategy focused on "standardization, professionalism, health, sustainability, and leapfrogging," aiming for brand success, scale formation, goal achievement, and profit creation [1] Financial Performance - In 2024, Yiling Pharmaceutical reported revenue of 6.513 billion yuan, a year-on-year decrease of 36.88%, and a net profit attributable to shareholders of -0.725 billion yuan, down 153.57% [2] - The decline in performance was attributed to the expiration of certain respiratory products, leading to reduced sales and inventory impairment losses, alongside rising raw material costs and sustained high R&D investments [2] - Despite the net loss, operating cash flow significantly improved, reaching 0.611 billion yuan, a year-on-year increase of 293%, with Q4 cash flow alone at 0.288 billion yuan, up over 26 times [2] - Accounts receivable decreased significantly, with a reduction of 1.176 billion yuan, a drop of 50%, and total liabilities decreased to 3.117 billion yuan, down 24.24 billion yuan or 43.75%, resulting in a debt-to-asset ratio decline of nearly 10 percentage points to 23.4% [2] R&D Investment - Yiling Pharmaceutical maintained a strong focus on R&D, with expenses reaching 0.908 billion yuan in 2024, accounting for 13.94% of revenue, reinforcing its leadership in traditional Chinese medicine innovation [3] - The company developed 17 innovative traditional Chinese medicines targeting eight major clinical disease systems, achieving industry leadership in cardiovascular and respiratory disease treatments [3] - New drug approvals included a treatment for allergic rhinitis and a new drug for gallbladder inflammation, with several patented traditional medicines included in the new medical insurance directory [3] Market Expansion and Strategic Initiatives - Yiling Pharmaceutical has registered products in over 50 countries and regions, actively entering the biopharmaceutical and health sectors, with recent approval for a breast cancer treatment [4] - Continuous R&D investment is expected to enhance product offerings and market share, while the transformation of technological innovations will improve product structure and competitiveness [4] - The company’s strategic focus on R&D and market trends positions it for greater growth in the pharmaceutical market [4] 2025 Outlook - In Q1 2025, Yiling Pharmaceutical reported revenue of 2.358 billion yuan and a net profit of 0.326 billion yuan, reflecting a year-on-year increase of 7.25% [5] - The company’s operating cash flow reached 0.34 billion yuan, nearly doubling year-on-year, with gross margin increasing by 2.34 percentage points to 53.82% [5] - The company aims to enhance its innovation capabilities, accelerate drug development, and implement a brand strategy while optimizing operational management and cost control [6]

Group 1 - Harbin city is focusing on attracting major investments by leveraging its resource and industrial advantages, particularly in six strategic emerging industries: aerospace, electronic information, high-end equipment, and biomedicine [1] - In 2024, Harbin has introduced 242 new investment projects with a total signed amount of 138.39 billion yuan, highlighting significant developments in various sectors [2] - The aerospace sector is seeing major projects such as the completion of the headquarters base for the largest domestic satellite manufacturer, which plans to produce 180 satellites annually, and a large drone manufacturing facility expected to produce 10,000 drones per year by 2025 [2] Group 2 - The equipment manufacturing sector is advancing with projects like the hydrogen energy comprehensive test base and a new energy shipbuilding and green port integration development base, both expected to commence construction this year [2] - In the electronic information industry, the largest domestic cloud computing center has been established, providing computing power services to 20 enterprises, while the silicon carbide industry park is expanding its production capacity [2] - The biomedicine sector is witnessing the completion of several production bases, including those for large-volume intravenous solutions and gene sequencing, indicating robust growth in healthcare-related industries [2] Group 3 - The investment bureau is innovating its investment attraction strategies by focusing on the transformation of scientific achievements and leveraging cultural tourism resources, enhancing collaboration with local universities and research institutions [3] - Major investment events such as the Asia-Pacific Winter Forum and the China-Russia Expo are being utilized to strengthen connections with key entrepreneurs and generate new cooperation projects [3] - The bureau is committed to improving the project landing service system to enhance the efficiency of the entire investment process from intention to production [3]

Group 1 - The core viewpoint of the news is the milestone significance of the first joint meeting of the Shantou, Chaozhou, and Jieyang cities, which aims to promote high-quality development in the Shantou-Chaozhou-Jieyang urban agglomeration through a comprehensive action plan for 2025-2026 [1][2] - The action plan establishes a top-level design for the urban agglomeration, including a rotating chair system for joint meetings and a leadership group composed of city leaders to enhance collaboration across various sectors [1][2] - The meeting marks a transition from "coordinated development" to "integrated construction," emphasizing the need for a more cohesive economic and infrastructural framework among the three cities [1][2] Group 2 - The action plan outlines four key areas of cooperation, with a total of 22 specific tasks and 29 priority projects for the current year, focusing on enhancing regional economic vitality [2][3] - A comprehensive transportation system is prioritized, aiming to establish a "one horizontal, four vertical, three ring" transportation framework to facilitate connectivity and economic integration [3] - The plan addresses the high degree of industrial homogeneity among the three cities by promoting the upgrading of traditional industries and the clustering of digital industries, thereby creating a modern industrial system that is collaborative and complementary [3]

4月29日，潍坊市市场监管局举行潍坊市专利成果对接会暨山东知识产权运营中心潍坊分中心揭牌仪式，此次活动推进潍坊市深入落实专 利转化运用专项行动，助力高校和科研机构存量专利转化。山东省市场监管局党组成员、副局长、一级巡视员、省知识产权局副局长于 智勇，潍坊市委副书记、市长刘建军出席会议并致辞。 据悉，山东省市场监管局党组成员、副局长、一级巡视员、省知识产权局副局长于智勇在致辞中对潍坊市知识产权转化运用方面取得的 成绩给予高度评价，希望各方以本次活动为契机，深化专利转化集成改革，强化知识产权运营体系建设，促进专利精准对接和落地转 化，以专利转化助推产业高质量发展。 齐鲁晚报.齐鲁壹点张晓慧 潍坊市委副书记、市长刘建军在致辞中表示，潍坊市将以此次对接活动为契机，进一步畅通专利对接转化渠道，深入推进产学研合作， 推动知识产权与实体经济深度融合，让更多优质专利成果在潍坊落地生根、开花结果。 活动现场，潍坊市副市长、市工商联主席陈端梅与山东省科创集团总经理王建新共同为山东知识产权运营中心潍坊分中心揭牌。现场同 步发布"潍坊动力装备产业专利池运营库"和"潍坊市专利转化资源库"等创新成果，集中展示了涵盖动力装备、光电、化工医 ...

本基金主要围绕杭州市打造全球创新策源地、成果转移转化首选地、颠覆性技术转移先行地建设， 重点突出对智能物联、生物医药、高端装备、新材料和绿色能源等五大产业生态圈及未来产业的科 创类项目进行投资。 杭州科创基金围绕初创项目全生命周期设立三类出资方式： 杭州科创基金2025年度子基金管理机构征集公告公布：为助力杭州打造创新活力之城，做优做 强"3+N"杭州产业基金集群，更好服务杭州市五大产业生态圈为代表的战略性新兴产业集聚发展， 杭州科创基金拟联合社会资本组建设立子基金，为吸引全国优秀机构积极参与上述子基金组建，现 公开征集子基金管理机构，有关事项公告如下： 杭州科创基金是"3+N"杭州产业基金集群之一，由杭州资本管理，以杭州资本所属企业杭州市科创 集团有限公司（以下简称杭州科创集团）为运营主体，功能定位为政策性的千亿级政府引导基金。 投资方向为"投早、投小、投科技"，投资阶段以初创期的科创投资为主，重点为全市人才创业、中 小企业创新、专精特新企业发展、科技成果转化提供政策性投融资服务。 对接需求请扫码 每日｜荐读 活动： 「2025中国产业资本峰会」圆满落幕，CVC成为投资行业枢纽！ 榜单： 「2025产业投资 ...

Group 1 - The Shenzhen Advanced Institute of Chinese Academy of Sciences has demonstrated impressive data regarding intellectual property, averaging 4.7 patents produced daily and 1.3 patents transferred or licensed over the past five years [1] - In 2024, the institute added 1,312 new patents, with over 527 patents licensed, and achieved a total contract amount of 350 million yuan from technology transfer [1] - As of April 26, the institute has cumulatively applied for 17,212 patents, with 7,039 authorized and 3,506 PCT applications, receiving a total of 13 awards at various levels for its high-quality intellectual property [1] Group 2 - The value of intellectual property is emphasized to be in its conversion effectiveness rather than sheer quantity, with 83.6% of high-value patents scoring above 8 in the institute's assessment [1] - The Shenzhen Advanced Institute is a pilot unit for revitalizing existing patents, implementing a systematic approach to inventory existing patents through classification and grading [2] - The institute promotes a principle of "inventory, promotion, and conversion" to accelerate the transformation of dormant patents into industrial momentum [2]

Core Viewpoint - The company reported a decline in revenue and net profit for Q1 2025, but showed signs of improvement compared to the previous quarter, with expectations for gradual transformation effects to materialize [1][2]. Financial Performance - In Q1 2025, the company achieved revenue of 1.078 billion yuan, a year-on-year decrease of 20.77% [1]. - The net profit attributable to shareholders was 102 million yuan, down 58.13% year-on-year [1]. - Compared to Q4 2024, the net profit increased by approximately 290 million yuan, and when excluding impairment losses, the net profit rose by about 180 million yuan [2]. Business Segments - The bioactive substances and medical terminal businesses remained stable in Q1 2025, with accelerated R&D, registration, and marketization of new raw materials and pipelines [2]. - The skin science innovation transformation business is still undergoing an adjustment period, prompting the chairman and general manager to take a more hands-on management approach [2]. - The company launched the first Class III medical device for facial skin quality improvement, which is expected to contribute positively to the medical terminal business [2]. Future Outlook - The company anticipates revenue growth for 2025-2027, with projected revenues of 5.774 billion, 6.362 billion, and 7.221 billion yuan, corresponding to growth rates of 7.5%, 10.2%, and 13.5% respectively [3]. - The net profit attributable to shareholders is expected to be 455 million, 530 million, and 628 million yuan for the same period, with growth rates of 161.2%, 16.3%, and 18.7% respectively [3]. - Earnings per share (EPS) are projected to be 0.94, 1.10, and 1.30 yuan per share for 2025-2027 [3].

"初阳台"杭州博士后科创沙龙为促进博士后产学研一体化，激发创新创业活力，搭建了新的平台。 今后，"初阳台"还将走进更多科研平台，来到更多拥有行业领先科研成果的博士后身边，努力促进他们 的项目落地，加速科技成果转化。 本次活动由杭州市人力社保局主办，萧山区有关单位承办。 这些项目的科技含量高、对标国际一流水平，都具有良好的市场前景，团队负责人也都有创业意 愿。但是，他们的项目在市场化方面处于早期，并且都有资金等方面的需求。"初阳台"旨在挖掘、筛选 出优质项目，邀请投融资机构、产业界代表来到活动现场与他们对接，并引导更多耐心资本投早、投 小，更多优势资源扶早、扶小，帮助前沿科技尽早迈向市场。 当前，博士后日益成为科技创新的重要生力军，活动以"初阳台"为名，寓意杭州要不断激发博士后 群体初生牛犊不怕虎的创新精神，精心呵护博士后人才初出茅庐的创业情怀。 "对于黑飞无人机，我们研发的这套侦测、干扰系统不仅'看得远、分得清、打得准'，而且设备体 积小、成本低。"近日，西安电子科技大学杭州研究院副研究员王尹圣带着科研项目走进"初阳台"杭州 博士后科创沙龙第三期活动，刚路演完，台下的投资机构代表、产业界代表、技术专家就为他提 ...